A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.

The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the d-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

[1]  James M. Stone,et al.  Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review , 2007, Journal of psychopharmacology.

[2]  Brian Knutson,et al.  Linking nucleus accumbens dopamine and blood oxygenation , 2007, Psychopharmacology.

[3]  K. Chopra,et al.  Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. , 2007, Indian journal of experimental biology.

[4]  A. Gunes,et al.  Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients , 2007, Psychopharmacology.

[5]  J. Newcomer,et al.  Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. , 2007, The Journal of clinical psychiatry.

[6]  J. Lieberman,et al.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. , 2006, The American journal of psychiatry.

[7]  P. Seeman.  Targeting the dopamine D2 receptor in schizophrenia , 2006, Expert opinion on therapeutic targets.

[8]  P. Masand,et al.  Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. , 2006, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[9]  Bai Lu,et al.  Regulation of Cortical Interneurons by Neurotrophins: From Development to Cognitive Disorders , 2006, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[10]  C. Marsden.  Dopamine: the rewarding years , 2006, British journal of pharmacology.

[11]  A. Guidotti,et al.  GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon , 2005, Psychopharmacology.

[12]  S. Fatemi,et al.  GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum , 2005, Schizophrenia Research.

[13]  D. Casey.  Pathophysiology of antipsychotic drug-induced movement disorders. , 2004, The Journal of clinical psychiatry.

[14]  L. Kochan,et al.  GABA and Schizophrenia: A Review of Basic Science and Clinical Studies , 2003, Journal of clinical psychopharmacology.

[15]  T. Ketter,et al.  The Diverse Roles of Anticonvulsants in Bipolar Disorders , 2003, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[16]  A. Guidotti,et al.  Dendritic Spine Hypoplasticity and Downregulation of Reelin and GABAergic Tone in Schizophrenia Vulnerability , 2001, Neurobiology of Disease.

[17]  F. Benes,et al.  GABAergic Interneurons: Implications for Understanding Schizophrenia and Bipolar Disorder , 2001, Neuropsychopharmacology.

[18]  J. Deeks,et al.  Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. , 2001, The Cochrane database of systematic reviews.

[19]  J. Seamans,et al.  Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex , 1999, Neuropsychopharmacology.

[20]  P. Worms,et al.  Dopamine-like activities of an aminopyridazine derivative, CM 30366: A behavioural study , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  V. Shukla,et al.  GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats. , 1985, Archives internationales de pharmacodynamie et de therapie.

[22]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[23]  M. Loza,et al.  A GABA, reelin, and the neurodevelopmental hypothesis of schizophrenia. , 2004, Critical reviews in neurobiology.

[24]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.

[25]  D J Sanger,et al.  Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  H. Spies,et al.  Effects of centrally acting drugs on serum prolactin levels in rhesus monkeys. , 1978, Neuroendocrinology.

[27]  K. Kuriyama,et al.  Blood-brain barrier to H3-γ-aminobutyric acid in normal and amino oxyacetic acid-treated animals ☆ , 1971 .